Search for: "NOVO NORDISK V SANOFI-AVENTIS"
Results 1 - 18
of 18
Sorted by Relevance
|
Sort by Date
8 Aug 2008, 3:01 pm
Novo Nordisk A/S v. [read post]
30 Jul 2008, 5:37 pm
Novo Nordisk v. [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
29 Jun 2011, 3:34 am
Cipla (Spicy IP) Effexor (Venlafaxine) – US: Intellipharmaceutics announces settlement for its generic version of Effexor (GenericsWeb) Eloxatin (Oxaliplatin) – US: Patent infringement complaint in response to Para IV certification: Sanofi-Aventis U.S. [read post]
8 Jul 2011, 11:04 am
June 23, 2011), the industry is trying again for clarity in the morass that is the FDA’s current regulation (if it can be called that) of off-label promotion.Earlier this week, seven large drug/device manufacturers (Allergan, Eli Lilly, J&J, Novartis, Novo Nordisk, and Sanofi-Aventis) filed a Citizen Petition with the FDA demanding that the Agency replace its current mish-mash of non-binding guidance documents, letters, press releases, criminal plea… [read post]
10 Jun 2010, 3:58 am
Kappos (Patent Docs) Products Allegra (Fexofenadine) - US: Patent infringement complaint following a Paragraph IV certification: Sanofi-Aventis U.S. [read post]
29 Dec 2010, 2:57 am
Sandoz, Inc (IPBiz) (Patent Docs) Plavix (Clopidogrel) – Brazil: Superior Court of Justice denies Plavix patent extension (IP tango) Prandin (Repaglinide) – US: Novo Nordisk and Sandoz settle infringement claims in Prandin dispute (Patent Docs) Prandin (Repaglinide) – US: Supreme Court petitioned to review Federal Circuit patent use code decision: Caraco v Novo Nordisk (FDA Law Blog) [read post]
17 Nov 2010, 1:48 am
PhotoCure (FDA Law Blog) US: Clinical trial requirements are top issue at FDA hearings on biosimilars (Patent Docs) Products Allegra (Fenofexadine, Psuedoephedrine) – US: Impax Laboratories receives final FDA approval for generic Allegra-D 60mg/120mg tablets (SmartBrief) Allegra (Fexofenadine) – US: Sanofi-Aventis, Aventisub, Carderm file patent infringement complaint against Aurolife, Aurobindo following Para IV certification (Patent Docs) Boniva (Ibandronate) –… [read post]
4 Nov 2019, 5:01 am
Sanofi-Aventis U.S. [read post]
27 Feb 2009, 5:00 am
(Patent Docs) Lexapro (Escitalopram) – US: Supreme Court refuses to hear appeal from Forest Lab’s allowing Caraco to continue bid to invalidate Lexapro patent despite Forest’s earlier covenant to sue (Law360) (Hal Wegner) Lotrel (Amlodipine) – US: Par and Novartis settle Lotrel lawsuit (Patent Docs) (GenericsWeb) Lovenox (Enoxaparin) – US: Amphastar antitrust claims nixed in Lovenox suit against Sanofi-Aventis (Law360)… [read post]
14 Dec 2007, 1:00 am
: (Patent Prospector) PharmaAggregate launches new online presence: (MaRS Blog - Innovation and Commercialization in Canada)Japan Plans Generic Drug Incentives to Cut Down Medical Costs: (MedIndia), Interesting commentary and article on generic/ innovator company patent settlements: (Generic Pharmaceuticals & IP), Global trends in commencement of patent actions by innovators: (Generic Pharmaceuticals & IP), Is marketing and not … [read post]
16 Jan 2009, 7:00 am
(IP Dragon) Patent strategies for foreign R&D work in China (Philip Brooks' Patent Infringement Updates) All clichés but still true: Intellectual Property Rights enforcement in China leaves room for improvement (IP Dragon) Recognition and protection of well-known trade marks (International Law Office) Revised Chinese patent law aims at quality, compulsory licensing (Intellectual Property Watch) Zen and the art of intellectual property in China (IP Dragon) Colombia… [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
9 Apr 2009, 9:27 am
KG v President of Gernamn Patent- und Markenamt (IPKat) Geobra Brandstätter assert copyright against vicar Pfarrer Markus Bomhard for using ‘deformed’ Playmobil figurines to depict biblical scenes (IPKat) (The IP Factor) Bundesgerichtshof on when a trade mark is distinctive enough to qualify for registration: STREETBALL case (Class 46) Still no infringement of Tuc cracker shape, says German appellate court (Class 46) Greece Well-known MOUYER trade… [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human Genome Sciences:… [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
